

Sanjeet S Dadwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2921415/publications.pdf>

Version: 2024-02-01

52
papers

1,646
citations

567281

15
h-index

302126

39
g-index

54
all docs

54
docs citations

54
times ranked

2849
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe Acute Respiratory Syndrome Coronavirus 2â€“Specific Monoclonal Antibody for the Treatment of Mild to Moderate Coronavirus Disease 2019 in Cancer Patients: A Single-Center Experience. Journal of Infectious Diseases, 2022, 225, 352-354.	4.0	7
2	Letermovir and maribavir for panâ€“resistant cytomegalovirus infection in a patient with haematologic malignancy: Consideration for combination therapy. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 699-702.	1.5	5
3	Variation in Clinical Practice and Attitudes on Antibacterial Management of Fever and Neutropenia in Patients With Hematologic Malignancy: A Survey of Cancer Centers Across the United States. Open Forum Infectious Diseases, 2022, 9, ofac005.	0.9	10
4	Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. Lancet Microbe, The, 2022, 3, e252-e264.	7.3	29
5	Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Cancer Medicine, 2022, 11, 21-27.	2.8	15
6	Infectious Disease Complications in Patients with Cancer. Critical Care Clinics, 2021, 37, 69-84.	2.6	12
7	American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients. Transplantation and Cellular Therapy, 2021, 27, 201-211.	1.2	23
8	Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Reports Medicine, 2021, 2, 100189.	6.5	149
9	DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study. Clinical Infectious Diseases, 2021, 73, e773-e781.	5.8	17
10	Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial. PharmacoEconomics - Open, 2021, 5, 469-473.	1.8	8
11	Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (<sc>HMAâ€“Ven</sc>) or liposomal daunorubicinâ€“cytarabine (<sc>CPX</sc>â€“351). American Journal of Hematology, 2021, 96, E196-E200.	4.1	10
12	Lateâ€“occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors. Cancer Medicine, 2021, 10, 2956-2966.	2.8	6
13	Can a Simple Stool Swab Predict Bacteremia in High-Risk Hematopoietic Cell Transplant Recipients?. Clinical Infectious Diseases, 2021, 73, 1266-1267.	5.8	2
14	Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience. Blood, 2021, 138, 3037-3037.	1.4	0
15	A Randomized Open Label Pilot Study of <i>Clostridium Butyricum</i> Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation. Blood, 2021, 138, 334-334.	1.4	1
16	The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type. Blood, 2021, 138, 1776-1776.	1.4	0
17	Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Viral Infections Post-HCT: Results from an Open-Label Cohort of a Phase 2 Trial. Blood, 2021, 138, 1760-1760.	1.4	3
18	594. Micafungin Prophylaxis in Acute Myeloid Leukemia Adult Patients Undergoing Induction Chemotherapy. Open Forum Infectious Diseases, 2021, 8, S400-S401.	0.9	0

#	ARTICLE	IF	CITATIONS
19	36. Evaluation of a Best Practice Alert (BPA) to Improve <i>Pneumocystis jirovecii</i> Prophylaxis Prescribing in Cancer Patients Receiving High-dose Corticosteroids in an Outpatient Setting. <i>Open Forum Infectious Diseases</i> , 2021, 8, S140-S140.	0.9	0
20	984. Diagnostic Utility of Bronchoalveolar Lavage <i>Pneumocystis jirovecii</i> DNA Polymerase Chain Reaction Assay in Patients with Hematological Malignancies and Hematopoietic Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2021, 8, S583-S583.	0.9	0
21	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 292-299.	2.0	13
22	Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1662-1664.	2.4	5
23	A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract. <i>Clinical Infectious Diseases</i> , 2020, 71, 2787-2795.	5.8	44
24	A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, 2777-2786.	5.8	53
25	Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1983-1994.	2.0	54
26	Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e322-e327.	2.0	32
27	Practice patterns and incidence of adenovirus infection in allogeneic hematopoietic cell transplant recipients: Multicenter survey of transplant centers in the United States. <i>Transplant Infectious Disease</i> , 2020, 22, e13283.	1.7	9
28	Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1697-1703.	2.0	6
29	Safety of Isavuconazonium Sulfate in Pediatrics Patients With Hematologic Malignancies and Hematopoietic Cell Transplantation With Invasive Fungal Infections: A Real World Experience. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, 261-265.	0.6	4
30	Persistent Value of the Stethoscope in the Age of COVID-19. <i>American Journal of Medicine</i> , 2020, 133, 1143-1150.	1.5	43
31	Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia. <i>Transplant Infectious Disease</i> , 2020, 22, e13233.	1.7	1
32	Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351). <i>Blood</i> , 2020, 136, 37-38.	1.4	2
33	Healthcare Resource Utilization in Transplant Patients Who Are at a Higher-Risk to Develop Cytomegalovirus Infection during Their Primary Transplant-Related Hospitalization. <i>Blood</i> , 2020, 136, 16-17.	1.4	0
34	Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e321-e330.	2.0	26
35	1760. Outcomes of Acyclovir-Resistant Herpes Simplex Virus Infections in Hematologic Malignancies and Hematopoietic Cell Transplant. <i>Open Forum Infectious Diseases</i> , 2019, 6, S647-S647.	0.9	0
36	Update on prevention of cytomegalovirus in hematopoietic cell transplantation. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 63-68.	3.1	2

#	ARTICLE	IF	CITATIONS
37	Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 265-269.	2.0	62
38	Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study. <i>Transplant Infectious Disease</i> , 2019, 21, e13007.	1.7	19
39	Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identification for Transplant) <i>Tj ETQq1 1 0.784314rgBT /Overlock 10</i>		
40	Draft Genome Sequence of a Clinical Isolate of <i>Fusarium fujikuroi</i> Isolated from a Male Patient with Acute Myeloid Leukemia. <i>Genome Announcements</i> , 2018, 6, .	0.8	5
41	A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection. <i>Expert Review of Vaccines</i> , 2018, 17, 889-911.	4.4	42
42	Recent advances in the molecular diagnosis of mucormycosis. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 845-854.	3.1	60
43	Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1828-1835.	2.0	15
44	Aseptic Meningitis as a Complication of Daratumumab Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e333-e335.	0.4	6
45	A Machine-Learning Sepsis Prediction Model for Patients Undergoing Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 711-711.	1.4	5
46	Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes. <i>Blood</i> , 2018, 132, 3416-3416.	1.4	1
47	Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience. <i>Blood</i> , 2018, 132, 3386-3386.	1.4	0
48	Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 377, 2433-2444.	27.0	796
49	Chronic Leptomeningitis and Spinal Intradural Mass Secondary to <i>Alternaria</i> Infection in a Patient with Ventriculoperitoneal Shunt. <i>Case Reports in Infectious Diseases</i> , 2016, 2016, 1-4.	0.5	1
50	Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2015, 94, 235-242.	2.2	22
51	Safety, Maximum Tolerated Dose and Immunogenicity of CMV-MVA-Triplex in Healthy Volunteers with or without Prior Immunity to CMV and Vaccinia. <i>Blood</i> , 2015, 126, 3108-3108.	1.4	1
52	Delayed Cytomegalovirus (cmv) Infection Following Hematopoietic Cell Transplantation (HCT): City of Hope (COH) Experience.. <i>Blood</i> , 2008, 112, 1155-1155.	1.4	1